Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic and Expression Analyses Define MUC17 and PCNX1 as Predictors of Chemotherapy Response in Breast Cancer.

Molecular cancer therapeutics - 1 Mar 2020

Al Amri Waleed S, Allinson Lisa M, Baxter Diana E, Bell Sandra M, Hanby Andrew M, Jones Stacey J, Shaaban Abeer M, Stead Lucy F, Verghese Eldo T, Hughes Thomas A

Abstract excerpt

Poor-prognosis breast cancers are treated with cytotoxic chemotherapy, but often without any guidance from therapy predictive markers because universally accepted markers are not currently available. Treatment failure, in the form of recurrences, is relatively common. We aimed to identify chemotherapy predictive markers and resistance pathways in breast cancer. Our hypothesis was that tumor cells remaining after...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carcinoma, Ductal, Breast

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Lobular

Share to Chemotherapy, Adjuvant

Share to Drug Resistance, Neoplasm

Share to Mucins

Share to Neoadjuvant Therapy

Share to Survival Rate

Source

Identifiers

PMID: 31879365
DOI: 10.1158/1535-7163.MCT-19-0940

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic and Expression Analyses Define MUC17 and PCNX1 as Predictors of Chemotherapy Response in Breast Cancer.PMID 31879365Read ↗

Genomic and transcriptomic analysis of breast cancer identifies novel signatures associated with response to neoadjuvant chemotherapySemantic proximity Read ↗

Integration of multi-omics data shows downregulation of mismatch repair, purin, and tubulin pathways in triple-negative chemotherapy-resistant breast tumorsSemantic proximity Read ↗

A Network Approach to Identify Biomarkers of Differential Chemotherapy Response Using Patient-Derived Xenografts of Triple-Negative Breast CancerSemantic proximity Read ↗

The Mutational Spectrum of Pre- and Post-Neoadjuvant Chemotherapy Triple-Negative Breast Cancers.Semantic proximity Read ↗

Circulating tumor DNA in neoadjuvant treated breast cancer reflects response and survivalSemantic proximity Read ↗

CDK16 + Luminal Progenitor Cell‐Like Tumor Cells Interacted with POSTN + Cancer‐Associated Fibroblasts Associate with Chemo‐Resistance In Breast CancerSemantic proximity Read ↗

CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer.Semantic proximity Read ↗

Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.Semantic proximity Read ↗

Immunogenomic Profiling and Pathological Response Results From a Clinical Trial of Docetaxel and Carboplatin in Triple Negative Breast CancerSemantic proximity Read ↗

Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer.Semantic proximity Read ↗

Whole-exome profiles of inflammatory breast cancer and pathological response to neoadjuvant chemotherapy.Semantic proximity Read ↗

Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.